1. Home
  2. SACH vs ADVM Comparison

SACH vs ADVM Comparison

Compare SACH & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SACH
  • ADVM
  • Stock Information
  • Founded
  • SACH 2010
  • ADVM 2006
  • Country
  • SACH United States
  • ADVM United States
  • Employees
  • SACH N/A
  • ADVM N/A
  • Industry
  • SACH Real Estate Investment Trusts
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SACH Real Estate
  • ADVM Health Care
  • Exchange
  • SACH Nasdaq
  • ADVM Nasdaq
  • Market Cap
  • SACH 46.7M
  • ADVM 47.4M
  • IPO Year
  • SACH 2017
  • ADVM 2014
  • Fundamental
  • Price
  • SACH $1.18
  • ADVM $2.17
  • Analyst Decision
  • SACH Hold
  • ADVM Strong Buy
  • Analyst Count
  • SACH 3
  • ADVM 5
  • Target Price
  • SACH $2.25
  • ADVM $23.80
  • AVG Volume (30 Days)
  • SACH 229.8K
  • ADVM 339.0K
  • Earning Date
  • SACH 08-13-2025
  • ADVM 08-11-2025
  • Dividend Yield
  • SACH 16.81%
  • ADVM N/A
  • EPS Growth
  • SACH N/A
  • ADVM N/A
  • EPS
  • SACH N/A
  • ADVM N/A
  • Revenue
  • SACH N/A
  • ADVM $1,000,000.00
  • Revenue This Year
  • SACH N/A
  • ADVM N/A
  • Revenue Next Year
  • SACH $4.52
  • ADVM $18.82
  • P/E Ratio
  • SACH N/A
  • ADVM N/A
  • Revenue Growth
  • SACH N/A
  • ADVM N/A
  • 52 Week Low
  • SACH $0.80
  • ADVM $1.78
  • 52 Week High
  • SACH $3.07
  • ADVM $10.14
  • Technical
  • Relative Strength Index (RSI)
  • SACH 60.46
  • ADVM 44.99
  • Support Level
  • SACH $1.08
  • ADVM $2.27
  • Resistance Level
  • SACH $1.12
  • ADVM $2.60
  • Average True Range (ATR)
  • SACH 0.06
  • ADVM 0.22
  • MACD
  • SACH -0.00
  • ADVM 0.01
  • Stochastic Oscillator
  • SACH 65.91
  • ADVM 22.40

About SACH Sachem Capital Corp.

Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

Share on Social Networks: